Skip to Main Content

Paper Details

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Proc Natl Acad Sci U S A
78
2017
Author NameAffiliation
Stephen E KurtzOregon Health & Science University
Christopher A EideOregon Health & Science University
Christopher A EideHoward Hughes Medical Institute, Oregon Health & Science University
Andy KaempfKnight Cancer Institute, Oregon Health & Science University
Vishesh KhannaOregon Health & Science University
Vishesh KhannaHoward Hughes Medical Institute, Oregon Health & Science University
Samantha L SavageOregon Health & Science University
Angela RofeltyOregon Health & Science University
Isabel EnglishOregon Health & Science University
Hibery HoOregon Health & Science University
Ravi Pandya
Michael W DeiningerHuntsman Cancer Institute, University of Utah
Robert H CollinsUT Southwestern Medical Center
Ronan SwordsUniversity of Miami School of Medicine
Justin M WattsUniversity of Miami School of Medicine
Daniel A PollyeaUniversity of Colorado School of Medicine
Bruno C MedeirosStanford University School of Medicine
Elie TraerOregon Health & Science University
Cristina E TognonOregon Health & Science University
Motomi MoriKnight Cancer Institute, Oregon Health & Science University
Motomi MoriOregon Health & Science University-Portland State University School of Public Health
Brian J DrukerOregon Health & Science University
Brian J DrukerHoward Hughes Medical Institute, Oregon Health & Science University
Jeffrey W TynerOregon Health & Science University
  • 1 - 24

Datasets